AstraZeneca PLC Hit by Generic Drugs and Crestor Shortfall

Published: Apr 25, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries took a heavy toll, underscoring the turnaround challenge facing Britain's second-largest drugmaker. Much of the damage was caused by loss of exclusivity on antipsychotic medicine Seroquel and heart drug Atacand in many markets. But the company's top-selling cholesterol fighter Crestor was also hit by generic competition in Canada, pricing pressure in Australia and worse-than-expected sales in the United States. The poor performance suggests new Chief Executive Pascal Soriot has his work cut out to reverse the fortunes of the struggling drugmaker, despite some tentative signs of improvement in a few growth areas.

Help employers find you! Check out all the jobs and post your resume.

Back to news